

( )

HDL

( / / )

( ECG -IHD)

/ /

NCEP(ATP III)

/ /

/

(OR = / CI: / / P= / )

(OR= / P= / )

HDL (OR= / P= / )

(OR= / P< / )

---

\*

\*\*



.()

HDL

.()

NHANES III<sup>3</sup>

.()

.()

ATP

.()

III<sup>1</sup>  
NCEP<sup>2</sup>

.()

.()

)

(

HDL

)

(

(

(

/

.()

ATP III-NCEP

.()

.()

:

: I

: II

<sup>3</sup> NHANES III: National Health And Nutrition Examination Survey III

<sup>1</sup> ATP III: Adult Treatment Panel III  
<sup>2</sup> NCEP: National Cholesterol Education Program

/

/

: ( I

« Standimeter »

)

BMI.( )

.(

ECG . ( )

/ /

I

Selectra 2 autoanalyzer (Vital " " specific,The Netherlands )

=<

colorimetric method ) (enzymatic glucose oxidase ( Pars Azmun Inc;Tehran, Iran)

HDL

( oxidase phenol aminoantipyrine cholesterol)

)

enzymatic – method glycerol -3 phosphate ( oxidase phenol aminoantipyrine Friedman ) LDL

: (

( Formula

: (

National cholesterol Education )

Program's Adult Treatment panel III " " (ATP III

: :

:

:

« WHO MONICA »

:



---



---



---



---

( / )	( / )	( / )	( / )	( / )	( / )
( / )	( / )	( / )	( / )	( / )	( / )
( / )	( / )	( / )	( / )	( / )	( / )
( / )	( / )	( / )	( / )	( / )	( / )
( / )	( / )	( / )	( / )	( / )	( / )

---



---

				(
--	--	--	--	---

---



---

/	/	/		
/	/	/		
/	/	/		
/	/	/		
/	/	/		( )
/	/	/	(	)

---



---

P.value	CI	OR	
/	( / / )	/	
/	( / /	/	( )
/	( / / )	/	
/	( / / )	/	
/	( / / )	/	

---

/

/

( )

/

---

ATP III

" ATP III"

-

-

" "

" "

.()

" NCEP" " WHO" /

.( ) /

NCEP /

WHO

- .()

" "

.(P< / )

WHO

.( )

Bruneck study

.()

/

/

.()

.()

.()

( OR= / P< / )

Atherosclerosis Risk in

Communities Study

.( )

COX

( OR= / ) . /

/

.( ) (OR = / )

.( )

.(OR = / )

"

"

.( )

.( )

OR= / ) .

.(

OR= /

HDL

.( )

ATP III

HDL

Kaunas

.( )

---

## References:

---

1. Anand SS, Yi Q, Gerstein H, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. *Circulation* 2003;108:420-425.
2. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 2001;285:2486-2497.
3. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. *Endocrinol Metab Clin N Am* 2004;33:351-375.
4. Bonora E, Kiechl S, Willeit J, et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome. *Diabetes Care* 2003;26:1251-1257.
5. Azizi F, Salehi P, Etemadi A, et al. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. *Diab Res Clin Pract* 2003;61:29-37.
6. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States Adults. *Circulation* 2004;110:1245-1250.
7. Wong ND. Intensified screening and treatment of the metabolic syndrome for cardiovascular risk reduction. *Prev Cardiol* 2005;8:47-54.
8. Ninomiya JK, L'Italien G, Criqui MH, et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutrition examination survey. *Circulation* 2004;109:42-46.
9. Vitari JA. The metabolic syndrome and cardiovascular disease. *Mount Sinai J Med* 2005;72:257-262.
10. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. *Diabetes Care* 2004;27:2444-2449.
11. Balkau B, Vernay M, Mhamdi L, et al. The incidence and persistence of the NCEP metabolic syndrome. The French D. E.S.I.R. study. *Diabet Metab* 2003;29:526-32.
12. Hunt KJ, Resendez RG, Williams K, et al. San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. *Circulation* 2004;110:1251-1257.
13. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA* 2002;288:2709-2716.
14. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. *Diabetes Care* 2005;28:385-390.
15. Zeller M, Steg PG, Ravisy J, et al. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. *Arch Intern Med* 2005;165:1192-8.
16. Cerniauskiene LR, Reklaitiene R, Luksiene DI, et al. Association of metabolic syndrome with ischemic heart disease among middle-aged Kaunas population. *Medicina* 2005;41:435-41.
17. Lindblad U, Langer RD, Wingard DL, et al. Metabolic syndrome and ischemic heart disease in elderly men and women. *Am J Epidemiol* 2001;153:481-9.